1a.Objectives (from AD-416):
Conduct clinical studies with the next generation of RVFV vaccines to determine their efficacy for disease control in Kenya.
1b.Approach (from AD-416):
Implement clinical challenge studies to evaluate the ability of available RVFV vaccines to stop viremia post challenge thus block viral transmission to the mosquito host. The initial portion of the project is to develop vaccination dose strategies by evaluating the host immune response to vaccination in relevant domestic African ruminant species. Project also requires the development of a challenge model in relevant domestic African ruminant species to evaluate the ability of RVFV vaccine(s) to prevent transmission to a relevant mosquito vector. Preferably, the challenge model will account for commonly occurring natural challenges by using mosquito transmission. The vaccine challenge model will require a sub agreement with the Onderstepoort Veterinary Institute due to lack of Animal Biosafety level 3 (ABSL-3) facilities in Kenya.
The desired long-term outcome of this research is to protect people in Africa from RVFV by developing a vaccine to protect domestic ruminants, which are the presumed reservoirs and are amplifying hosts. The primary objective is to develop the infrastructure necessary to conduct clinical studies with the attenuated and next generation of RVFV vaccines to determine their efficacy for disease control. Designs for the renovations and construction contracts were established. Renovations are in progress and an ARS team reviewed the progress in September 2011. The animal containment facility continues to be improved. The work on the perimeter concrete wall continued during the quarter but is yet to be completed. It is about 2/3 done. Twenty personnel who will be involved directly or indirectly with the project activities were given the first dose of inactivated RVF vaccine (TSI-GSD-200). They will be checked for sero-conversion at 28 days post inoculation.